The a2 Milk Company to enter China’s pediatric supplements market

The a2 Milk Company is ramping up its infant nutrition business in China with the upcoming launch of four pediatric supplements in Q3.
The products, to be launched under the brand a2 Zhi Yi, would span immunity, anti-allergy, gut health, and brain and eye health functions.
According to the company, the pediatric supplements market in China is worth NZD$8bn (US$4.76bn), which represents 15% to 20% of the total supplements market in China.
Otsuka Pharma beefs up POCARI SWEAT production in China

Otsuka Pharmaceutical Co. Ltd, the owner of the electrolyte drink POCARI SWEAT, is ramping up production in China with a newly opened factory in Tianjin.
The Japanese company expects to produce 300 million 500 ml POCARI SWEAT bottles annually in the newly opened Tianjin Second Factory.
Demand for hydration and electrolyte beverages is rising in Northern China, a trend the new Tianjin factory will address, according to Otsuka Pharmaceutical.
Hindustan Unilever to fully acquire clean-label, women’s health firm for US$90M

Hindustan Unilever is fully acquiring clean-label protein and women’s health supplements firm OZiva for INR 8.24 billion (US$90.9 million).
This makes OZiva, also known as Zywie Ventures Private Limited, a wholly owned subsidiary of Hindustan Unilever (HUL).
At the same time, HUL will sell all its stakes (19.8%) in Nutritionalab Private Limited, the company behind the brand Wellbeing Nutrition, to USV Private Limited.
Blackmores CEO to head new entity set up by parent company

Alastair Symington, CEO of Blackmores Limited, will be leading a new entity set up by parent company Kirin Holdings Company.
The new entity, named Kirin Health Science International (KHSI) Pty Ltd, will come into operation from April 1, 2026.
Headquartered in Sydney, Australia, the company will oversee Kirin’s B2C health science businesses outside Japan.
Bayer pours €5M into micronutrient supplement factory, R&D in Indonesia

Bayer has invested €5 million (US$5.9m) in its multiple micronutrient supplement production line and R&D center in Indonesia.
Part of the investment (€1.4m) went to upgrading the company’s production site located at the Bayer Supply Center Consumer Health Cimanggis, Depok.
The upgrades include introducing digitalization and automation to optimize production output by around 20%.




